Reduce Time to Market With Pre-IND Meetings
Did you know reducing time to market is one of the biggest challenges companies face when seeking FDA approval on their drug development plans and clinical trials?
Olga Carroll, Alira Health’s Vice President, Regulatory, and Prasanna Palle, Senior Associate Regulatory Consultant offer tips to reduce time to market with Pre-IND Meetings.
To learn more about Alira Health’s Regulatory practice, click here.
To connect with Olga Carroll, click here.